Retlirafusp Biosimilar – Anti-CD274 mAb – Research Grade

Description of Retlirafusp Biosimilar - Anti-CD274 mAb - Research Grade

Retlirafusp Biosimilar – Anti-CD274 mAb – Research Grade

Introduction

Retlirafusp Biosimilar, also known as anti-CD274 monoclonal antibody, is a research grade therapeutic antibody that targets the protein CD274. This biosimilar is a highly specific and potent inhibitor of CD274, making it a promising candidate for the treatment of various diseases.

Structure

Retlirafusp Biosimilar is a monoclonal antibody, meaning it is produced from a single type of immune cell. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chains consist of a constant region and a variable region, while the light chains only have a variable region. The variable regions contain the antigen-binding site, which is responsible for the specificity of the antibody.

Activity

Retlirafusp Biosimilar specifically targets the protein CD274, also known as programmed cell death ligand 1 (PD-L1). CD274 is a cell surface protein that plays a key role in regulating the immune response. It is expressed on various types of cells, including cancer cells, and binds to its receptor, PD-1, on immune cells, leading to suppression of immune response. By inhibiting the interaction between CD274 and PD-1, Retlirafusp Biosimilar can enhance the immune response and potentially lead to the destruction of cancer cells.
In addition to its anti-cancer activity, Retlirafusp Biosimilar has also shown potential in treating autoimmune diseases. By blocking the CD274-PD-1 interaction, it can prevent the suppression of the immune response and potentially reduce the symptoms of autoimmune diseases.

Application

Retlirafusp Biosimilar is currently being studied in preclinical and clinical trials for its potential use in various types of cancer, including lung cancer, melanoma, and lymphoma. It is also being investigated for its potential in treating autoimmune diseases such as rheumatoid arthritis and lupus.
As a research grade antibody, Retlirafusp Biosimilar is also widely used in laboratory experiments to study the role of CD274 in different diseases and to develop new therapies targeting this protein.

Conclusion

Retlirafusp Biosimilar is a highly specific and potent inhibitor of CD274, making it a promising candidate for the treatment of cancer and autoimmune diseases. Its unique structure and activity make it a valuable tool for both research and potential therapeutic applications. Further studies and clinical trials are needed to fully understand the potential of this biosimilar in treating various diseases.